Benjamin Ruf
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 16
- Cancer Immunotherapy and Biomarkers 15
- Immunology 12
- T-cell and B-cell Immunology 5
- Immune cells in cancer 4
- IL-33, ST2, and ILC Pathways 3
- Co-authors
- Tim F. Greten (16 shared papers)Bernd Heinrich (8 shared papers)Firouzeh Korangy (6 shared papers)Xin Wei Wang (3 shared papers)Chi Ma (10 shared papers)Simon Wabitsch (8 shared papers)Lichun Ma (2 shared papers)Laurence P. Diggs (6 shared papers)
- Journals
- Gut (3 papers)Journal of Hepatology (2 papers)iScience (2 papers)Molecular Therapy — Oncolytics (2 papers)Frontiers in Medicine (1 paper)
- Partner nations
- United StatesGermanyIreland
In The Last Decade
Benjamin Ruf
32 papers receiving 1.7k citations
Benjamin Ruf's Hit Papers
Peers
Comparison fields: 5 of 73
- Hepatology 421
- Oncology 565
- Immunology 381
- Cancer Research 87
- Physiology 22
Countries citing papers authored by Benjamin Ruf
This map shows the geographic impact of Benjamin Ruf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Ruf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Ruf more than expected).
Fields of papers citing papers by Benjamin Ruf
This network shows the impact of papers produced by Benjamin Ruf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Ruf. The network helps show where Benjamin Ruf may publish in the future.
Co-authors
The 25 scholars most cited alongside Benjamin Ruf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 241 | |
| 2 | 2020 | 227 | |
| 3 | Biomarkers for immunotherapy of hepatocellular carcinoma Hit paper breakdown → | 2023 | 155 |
| 4 | 2023 | 129 | |
| 5 | 2020 | 128 | |
| 6 | 2022 | 125 | |
| 7 | 2021 | 92 | |
| 8 | 2023 | 91 | |
| 9 | 2022 | 71 | |
| 10 | 2020 | 69 | |
| 11 | 2023 | 60 | |
| 12 | 2021 | 46 | |
| 13 | 2016 | 34 | |
| 14 | 2019 | 30 | |
| 15 | 2015 | 26 | |
| 16 | 2021 | 26 | |
| 17 | 2025 | 25 | |
| 18 | 2022 | 21 | |
| 19 | 2020 | 20 | |
| 20 | 2024 | 20 |
About Benjamin Ruf
Benjamin Ruf is a scholar working on Oncology, Immunology, Hepatology, Physiology and Genetics, having authored 34 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (15 papers), T-cell and B-cell Immunology (5 papers), Immune cells in cancer (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Virus-based gene therapy research (3 papers), IL-33, ST2, and ILC Pathways (3 papers) and Adenosine and Purinergic Signaling (2 papers). The work is most often cited by research in Hepatology (421 citations), Oncology (565 citations), Immunology (381 citations), Cancer Research (87 citations) and Physiology (22 citations). Benjamin Ruf has collaborated with scholars based in United States, Germany and Ireland. Frequent co-authors include Tim F. Greten, Bernd Heinrich, Firouzeh Korangy, Xin Wei Wang, Chi Ma, Simon Wabitsch, Lichun Ma, Laurence P. Diggs, Augusto Villanueva and Eytan Ruppin. Their work appears in journals such as Gut, Journal of Hepatology, iScience, Molecular Therapy — Oncolytics and Frontiers in Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.